# ACADIA Pharmaceuticals Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ACADIA Pharmaceuticals Inc).

## Overview

ACADIA Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on commercializing and developing therapies for central nervous system and rare diseases. Its current business is anchored by two U.S.-approved products: NUPLAZID (pimavanserin) and DAYBUE (trofinetide). The company runs a specialty-pharmacy-centric distribution model and supports prescribing through field-based specialists and patient access services. Manufacturing and supply are largely outsourced, with a Swiss subsidiary (Acadia Pharmaceuticals GmbH) managing key intellectual property and the global supply chain for pimavanserin API manufactured in Switzerland.

## Products & services

• NUPLAZID (pimavanserin) for approved CNS indication(s)
• DAYBUE (trofinetide) for Rett syndrome
• Acadia Connect patient access, reimbursement & adherence support
• Field-based U.S. sales specialists and medical education programs
• Pipeline R&D (e.g., ACP-101, ACP-204; remlifanserin programs)

- **NUPLAZID (pimavanserin)** (65%) — Commercial sales of NUPLAZID via specialty channels, supported by marketing and distribution partners.
- **DAYBUE (trofinetide)** (30%) — Commercial sales of DAYBUE for Rett syndrome supported by rare disease field teams and patient services.
- **Other revenue (e.g., PRV sale/other)** (5%) — Non-recurring or ancillary items such as proceeds from Rare Pediatric Disease PRV sales when applicable.

- NUPLAZID (pimavanserin) for approved CNS indication(s)
- DAYBUE (trofinetide) for Rett syndrome
- Acadia Connect hub: access, reimbursement, adherence support
- U.S. field sales specialists and prescriber education campaigns
- Pipeline R&D (ACP-101, ACP-204; remlifanserin programs)

## Customers

ACADIA’s direct customers are a limited set of U.S. specialty pharmacies and specialty distributors that purchase product and then dispense or resell into care settings. Specialty pharmacies dispense NUPLAZID to patients based on prescriptions, while specialty distributors sell into government facilities, long-term care pharmacies, and inpatient hospital pharmacies. For DAYBUE, the company targets physicians treating Rett syndrome patients, including Centers of Excellence and high-volume institutions, and supports initiation and persistence through its Acadia Connect hub. Ultimate demand is driven by prescriber adoption, patient identification/diagnosis, and payer coverage decisions that determine access and out-of-pocket costs.

- **Specialty pharmacies (U.S.)** (primary) — Purchase NUPLAZID (and potentially DAYBUE) and dispense to patients; value reliable supply, reimbursement support, and patient services.
- **Specialty distributors (U.S.)** (primary) — Buy product for resale into government facilities, long-term care pharmacies, and inpatient hospital pharmacies; value compliant distribution and continuity of supply.
- **Prescribers and treatment centers** (secondary) — Physicians and institutions (including Rett Centers of Excellence) drive prescribing decisions; influenced by clinical data, education, and patient support infrastructure.
- **Payors (commercial and government)** (secondary) — Determine coverage, prior authorization, and patient cost-sharing that directly affects uptake and persistence for specialty therapies.

- Specialty pharmacies dispensing NUPLAZID to patients with prescriptions
- Specialty distributors supplying government and institutional channels
- Neurology/psychiatry prescribers driving NUPLAZID utilization
- Rett syndrome specialists and Centers of Excellence prescribing DAYBUE
- Commercial and government payors influencing access via coverage terms
- Patients/caregivers relying on access and adherence support via Acadia Connect

## Geography

ACADIA is headquartered in the United States and currently commercializes NUPLAZID and DAYBUE primarily in the U.S. market. A key operational feature is its Swiss subsidiary, Acadia Pharmaceuticals GmbH, which holds licensed worldwide intellectual property rights for pimavanserin in certain indications and manages the worldwide supply chain for pimavanserin API. The pimavanserin API has been manufactured in Switzerland for over a decade through a contract manufacturer (Siegfried AG), with inventory held in a Swiss contract warehouse. The company indicates it may pursue commercialization of DAYBUE outside the U.S. either independently or through strategic alliances, making future ex-U.S. execution and regulatory approvals an important swing factor.

- United States is the core commercial market for NUPLAZID and DAYBUE
- Switzerland is central to pimavanserin API manufacturing and inventory
- Acadia Pharmaceuticals GmbH manages pimavanserin IP and global API supply
- Contract manufacturing footprint creates cross-border supply dependencies
- Potential future ex-U.S. DAYBUE markets may be pursued via partners or direct

## Strategy

ACADIA’s near-term strategy centers on sustaining and expanding the NUPLAZID franchise while scaling DAYBUE adoption in Rett syndrome through prescriber education and patient activation. The company is investing in commercial infrastructure, including rare disease field specialists and patient access services, to reduce friction in reimbursement and therapy initiation. It is also allocating capital to advance a pipeline of CNS/rare disease candidates (including programs referenced as ACP-101, ACP-204 and remlifanserin) to diversify beyond the two marketed products. Internationally, management highlights optionality to commercialize DAYBUE outside the U.S. either directly or through strategic alliances, contingent on regulatory approvals.

- **Scale DAYBUE adoption in Rett syndrome in the U.S.** (short-term) — DAYBUE growth depends on specialist penetration, diagnosis, and access execution.
- **Sustain and defend the NUPLAZID franchise** (short-term) — A large portion of revenue is tied to continued demand and channel effectiveness.
- **Diversify through pipeline development and business development** (medium-term) — Reducing dependence on two products lowers concentration risk and supports longer-term growth.

- Support NUPLAZID demand via consumer activation and franchise marketing
- Expand DAYBUE field team and education to make it standard of care in Rett
- Use Acadia Connect to improve access, reimbursement, and adherence
- Advance pipeline (ACP-101, ACP-204, remlifanserin) to broaden portfolio
- Pursue ex-U.S. DAYBUE commercialization via alliances or direct approach
- Maintain outsourced manufacturing and supply-chain resilience for API/drug product

## Risks

Revenue concentration risk is high because the company’s prospects are highly dependent on maintaining and growing sales of NUPLAZID and DAYBUE, which in turn depend on diagnosis rates, prescriber adoption, and payer coverage. Distribution is concentrated in a limited number of specialty pharmacies and specialty distributors, and the loss or underperformance of these channels could disrupt sales and collections. The supply chain relies on third-party manufacturers (including Swiss API production for pimavanserin and contract drug product manufacturing), creating exposure to quality issues, regulatory actions, and recalls that could halt commercialization. Like other biopharma companies, ACADIA faces clinical development and regulatory approval risk for pipeline assets and for any ex-U.S. expansion of trofinetide, as well as cybersecurity and data privacy risks across its own systems and third-party vendors.

- **Customer concentration in specialty pharmacies/distributors** [high] — A limited number of U.S.-based customers accounted for ~79% of NUPLAZID product revenue and 44% of total product revenue (FY2025), increasing exposure to channel disruption or contract changes.
- **Third-party manufacturing and regulatory enforcement risk** [high] — API and drug product manufacturing are outsourced; regulatory actions (e.g., recalls, warning letters, site enforcement) could restrict manufacturing/marketing or force discontinuation.
- **Dependence on continued product adoption and payer coverage** [high] — If physicians/patients do not adopt products or if coverage/out-of-pocket costs worsen, demand and revenue can decline despite commercial investment.
- **Data privacy and cybersecurity incidents (including third parties)** [medium] — Compromises of IT systems or vendor systems can cause operational disruption, regulatory investigations, litigation, and reputational harm.
- **Tax structure and transfer pricing challenges involving Swiss subsidiary** [medium] — Tax authorities may challenge intercompany pricing and income allocation related to Acadia GmbH and licensed IP, potentially increasing taxes, interest, and penalties.

- High dependence on NUPLAZID and DAYBUE commercialization success
- Customer concentration in a small set of specialty pharmacies/distributors
- Third-party manufacturing and quality/regulatory compliance failures
- Regulatory actions (warning letters, recalls, approval delays) can halt sales
- Payer coverage and patient out-of-pocket costs can limit uptake and persistence
- Cybersecurity and data privacy incidents across vendors and internal systems
- International tax and transfer pricing challenges tied to Swiss subsidiary structure

## Accounting

Reported revenue and receivables are influenced by the specialty pharmacy/distributor channel model, including estimates related to returns, chargebacks, rebates, and other variable consideration typical for U.S. pharma net sales. Income tax accounting is a key judgment area: the company previously maintained a full valuation allowance against deferred tax assets but reduced the valuation allowance in 2025 after achieving cumulative three-year profitability, which can materially affect tax expense and net income. The company’s international structure (including licensing IP to its Swiss subsidiary) increases complexity around uncertain tax positions and intercompany arrangements, which can drive quarter-to-quarter tax rate volatility. Non-recurring transactions can affect comparability, such as the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) following DAYBUE approval.

- **Deferred tax assets and valuation allowance release** — Tax expense, net income, and effective tax rate volatility
- **Uncertain tax positions and intercompany arrangements (U.S./Switzerland)** — Potential tax assessments, penalties, and cash flow impacts
- **Non-recurring asset sale gains (PRV)** — Other income and comparability across periods

- Net product revenue depends on gross-to-net estimates (rebates/returns)
- Channel model affects timing of revenue, receivables, and deductions
- Deferred tax asset valuation allowance changes can swing tax expense
- Uncertain tax positions/transfer pricing tied to Swiss IP structure
- Non-recurring gains (e.g., PRV sale) affect period-to-period comparability

---

*Last updated: 2026-08-11T04:46:16.911044+00:00*